This bill amends Section 7362(b) of the National Defense Authorization Act for Fiscal Year 2020 (codified at 15 U.S.C. 8962(b)) by replacing the year "2024" with "2030." The statutory change extends the period during which Congress may authorize appropriations for PFAS (per- and polyfluoroalkyl substances) research and development carried out by the Environmental Protection Agency.
Why it matters: the text is narrowly targeted but consequential in practice. By extending the authorization window, the bill preserves the EPA’s statutory authority to receive Congressional appropriations for PFAS R&D activities for six additional years—removing an immediate statutory barrier to continuing or initiating multi-year research, monitoring, and remediation programs tied to that authority.
At a Glance
What It Does
The bill amends 15 U.S.C. 8962(b) to change the authorization expiration year from 2024 to 2030, effectively extending the period during which Congress can authorize appropriations for EPA PFAS research and development programs.
Who It Affects
Directly affects the Environmental Protection Agency and entities that receive EPA PFAS R&D grants or contracts—universities, federal and state labs, consultants, and contractors working on detection, toxicity, and remediation projects.
Why It Matters
Extending the authorization preserves the legal basis for funding PFAS-related science and contracts, which matters to program managers planning multi-year studies and to stakeholders relying on federal research to inform regulation, remediation, and standards.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The bill is a single, technical amendment: it alters the expiration date in the statute that authorizes Congress to appropriate funds for EPA PFAS research and development. The original provision—added by the National Defense Authorization Act for Fiscal Year 2020—set a sunset year of 2024 for that authorization; this bill moves the sunset to 2030.
That change does not itself appropriate money or change the statutory text governing what kinds of research or partnerships are permissible. Instead, it keeps open the window during which appropriators may provide funds to the EPA under that existing statutory authority.
Practically, that means EPA program offices can continue to seek grant, cooperative agreement, and contract funding tied to the PFAS R&D authorization without the legal complication of an expired authorization.For stakeholders planning long-term work—academic research projects with multi-year timelines, statewide monitoring networks, or private remediation firms aligning investments to expected federal activity—the extension reduces the risk that a program’s statutory funding basis will lapse mid-project. At the same time, because the bill does not set appropriation levels, the ability to fund projects still depends on Congress including dollars in appropriations or authorizing committees proposing funding levels.Finally, the amendment is time-bound: extending authorization to 2030 preserves a sunset that forces a future policy decision rather than making the authority permanent.
That preserves congressional leverage over program scope and funding while giving agencies and partners breathing room to continue and plan PFAS R&D work over the next several years.
The Five Things You Need to Know
The bill amends Section 7362(b) of the NDAA for FY2020, codified at 15 U.S.C. 8962(b).
It replaces the expiration year "2024" in that subsection with "2030," extending the authorization by six years.
The change extends authorization of appropriations only; the bill does not appropriate funds or specify funding levels.
The statutory extension preserves EPA’s ability to receive appropriations for PFAS R&D grants, cooperative agreements, and contracts under the existing authority.
The amendment is temporal—it keeps a sunset (now 2030) rather than creating a permanent authorization or changing program scope or oversight.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Short title
Provides the act’s short name: the "PFAS Research and Development Reauthorization Act of 2025." Short titles are administrative, but they identify the statute for use in reports, signage on appropriations, and agency rulemaking references.
Amend 15 U.S.C. 8962(b) — extend authorization date to 2030
Strikes the year "2024" and inserts "2030" in the cited subsection. The practical legal effect is narrow: where the existing statute allowed Congress to authorize appropriations for EPA PFAS R&D through 2024, it will now allow such authorizations through 2030. Because the provision is an amendment to an authorizing statute rather than an appropriations act, it neither obligates nor disburses funds; it simply preserves the statutory authorization on which future appropriations can be based.
What agencies and appropriators will do next
With the authorization window extended, EPA and program partners retain a statutory hook to request or accept PFAS R&D funds under 15 U.S.C. 8962. Agencies planning multi-year awards or interagency research partnerships can cite continued authorization when designing solicitations and contracts. Appropriators still must act: extension removes a legal barrier to funding but does not compel Congress to allocate dollars or change oversight, reporting, or performance requirements attached to any future appropriations.
This bill is one of many.
Codify tracks hundreds of bills on Environment across all five countries.
Explore Environment in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Environmental Protection Agency program offices — retain statutory authority to seek and manage PFAS R&D funds, reducing legal disruption to ongoing projects.
- University and federal research labs — keep eligibility paths open for federal grants and cooperative agreements tied to EPA PFAS research priorities, aiding multi-year study planning.
- State environmental and public health agencies — preserve federal research partnerships and data streams that states use to develop monitoring and remediation programs.
- Consulting and remediation firms — maintain the prospect of contract opportunities and federally funded demonstration projects that support technology deployment.
- Communities and downstream water utilities — indirectly benefit from continued federal research that refines detection methods, health assessments, and remediation approaches.
Who Bears the Cost
- Congressional appropriations process/taxpayers — extending authorization creates ongoing opportunities to spend; any eventual funding comes from federal budgets and taxpayers.
- Appropriations committees and budget drafters — must decide whether to allocate funds within constrained budgets and prioritize PFAS against other program needs.
- Small agencies or programs competing for limited PFAS R&D dollars — extension may maintain competition and uncertainty about which projects receive funding.
- EPA administrative resources — managing extended multi-year programs and interagency coordination consumes program staff time and compliance resources.
- Private-sector entities seeking certainty — firms that planned on a permanent authorization may still face funding uncertainty until appropriations are enacted, creating planning costs.
Key Issues
The Core Tension
The central dilemma is continuity versus control: the bill supports continuity in federally sponsored PFAS research by extending the authorization window, but it preserves Congress’s budgetary control—meaning the extension reduces legal uncertainty without guaranteeing funding, leaving program planning dependent on future appropriations choices.
Two implementation realities matter and create open questions. First, authorizations do not equal appropriations: extending the statutory window removes a legal impediment to funding but does not guarantee any dollars.
Programs that rely on annual appropriations will still face budgetary competition; multi-year contracts may remain vulnerable if appropriations are reduced or withheld. Second, the bill changes only a date.
It does not adjust program scope, performance metrics, reporting requirements, or interagency roles spelled out elsewhere. That makes the amendment administratively low-friction but shifts the substantive debates—about what to fund, how much, and with which performance expectations—back to appropriations and oversight processes.
The amendment’s time-bound design (a new sunset in 2030) preserves congressional leverage but also imposes planning friction: program managers get medium-term stability but must prepare for another reauthorization decision before work that extends past 2030 can proceed without renewed statutory authority. Finally, because PFAS R&D informs regulatory standards and remediation practices, an extended authorization reduces the legal risk of disrupting science that regulators rely on; however, without parallel clarity on appropriations or statutory mandates linking research to regulatory timelines, stakeholders may find federal research efforts insufficiently aligned with state and local cleanup needs.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.